Lilly Unveils Q4 2025 Financial Results and 2026 Outlook
On February 4, 2026, Eli Lilly and Company announced its financial results for the fourth quarter of 2025. The company reported significant growth in revenue and earnings, indicating strong performance driven by key products.
Lilly’s Q4 2025 Financial Overview
In the fourth quarter of 2025, Eli Lilly recorded revenue of $19.3 billion, marking a 43% increase compared to the same period in 2024. This growth was primarily fueled by a 46% rise in product volume, particularly from Mounjaro and Zepbound.
- Revenue Breakdown:
- U.S. revenue: $12.9 billion (43% increase)
- International revenue: $6.4 billion (43% increase)
- Net Income: Reported net income reached $6.6 billion, up 50% year-over-year.
- Earnings per Share (EPS): Increased by 51% to $7.39 on a reported basis.
Key Product Performances
The growth in revenue was largely driven by the following products:
| Product | Q4 2025 Revenue ($ millions) | Year-over-Year Growth (%) |
|---|---|---|
| Mounjaro | 7,409 | 110 |
| Zepbound | 4,261 | 123 |
| Verzenio | 1,604 | 3 |
Regulatory and Pipeline Updates
Lilly made significant regulatory advancements, including:
- FDA approval for the Kwikpen delivery system of tirzepatide.
- Expanded indication for Jaypirca, facilitating treatment for certain blood cancers.
- Submissions for orforglipron aimed at treating obesity and type 2 diabetes in the U.S., Japan, and EU.
Additional positive developments from clinical trials included:
- Taltz and Zepbound achieving promising results in treating active psoriatic arthritis and obesity.
- Orforglipron demonstrating efficacy for patients switching from injectable incretins.
- Retatrutide effectively assisting individuals with obesity and knee osteoarthritis.
Financial Guidance for 2026
Looking ahead, Lilly issued guidance for 2026, projecting revenues between $80 billion and $83 billion. Expected non-GAAP EPS is anticipated to be between $33.50 and $35.00. This outlook highlights the company’s ongoing confidence in its established and developing product lines.
“2025 was an important year for Lilly,” said David A. Ricks, the company’s chair and CEO. “With a deep pipeline and new partnerships, we are committed to expanding global health access.”
This period of growth positions Lilly to continue reaching new patients and enhancing its impact in the pharmaceutical industry.
Conclusion
Eli Lilly’s robust performance in Q4 2025 showcases its strong market position and innovative product strategy. The company’s commitment to expanding access to obesity treatments and continued investment in research and development underscores its goals for future growth.
